108 related articles for article (PubMed ID: 25123375)
21. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
[TBL] [Abstract][Full Text] [Related]
22. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
23. Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model.
Eldin NE; Abu Lila AS; Kawazoe K; Elnahas HM; Mahdy MA; Ishida T
Eur J Pharm Sci; 2016 Jan; 81():60-6. PubMed ID: 26415830
[TBL] [Abstract][Full Text] [Related]
24. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
25. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
26. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Leclercq S; Gueugnon F; Boutin B; Guillot F; Blanquart C; Rogel A; Padieu M; Pouliquen D; Fonteneau JF; Grégoire M
Eur Respir J; 2011 Nov; 38(5):1105-16. PubMed ID: 21540307
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.
Abu Lila AS; Kato C; Fukushima M; Huang CL; Wada H; Ishida T
Int J Oncol; 2016 Apr; 48(4):1399-407. PubMed ID: 26847426
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.
Lam SK; Li YY; Zheng CY; Ho JC
Int J Oncol; 2015 Jan; 46(1):113-22. PubMed ID: 25335113
[TBL] [Abstract][Full Text] [Related]
29. ADAM10 mediates malignant pleural mesothelioma invasiveness.
Sépult C; Bellefroid M; Rocks N; Donati K; Gérard C; Gilles C; Ludwig A; Duysinx B; Noël A; Cataldo D
Oncogene; 2019 May; 38(18):3521-3534. PubMed ID: 30651596
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Khong A; Cleaver AL; Fahmi Alatas M; Wylie BC; Connor T; Fisher SA; Broomfield S; Lesterhuis WJ; Currie AJ; Lake RA; Robinson BW
BMC Cancer; 2014 Dec; 14():969. PubMed ID: 25518732
[TBL] [Abstract][Full Text] [Related]
31. Suramin inhibits the growth of malignant mesothelioma in vitro, and in vivo, in murine flank and intraperitoneal models.
Cook JW; Sterman DH; Singhal S; Smythe WR; Kaiser LR
Lung Cancer; 2003 Dec; 42(3):263-74. PubMed ID: 14644513
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions.
Thomas R; Cheah HM; Creaney J; Turlach BA; Lee YC
Chest; 2016 Jun; 149(6):1494-500. PubMed ID: 26836920
[TBL] [Abstract][Full Text] [Related]
33. Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma.
Merritt RE; Yamada RE; Wasif N; Crystal RG; Korst RJ
Ann Thorac Surg; 2004 Sep; 78(3):1042-51; discussion 1042-51. PubMed ID: 15337045
[TBL] [Abstract][Full Text] [Related]
34. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.
Hegmans JP; Hemmes A; Hammad H; Boon L; Hoogsteden HC; Lambrecht BN
Eur Respir J; 2006 Jun; 27(6):1086-95. PubMed ID: 16540497
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma.
Cornelissen R; Lievense LA; Robertus JL; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
Lung Cancer; 2015 Jun; 88(3):332-7. PubMed ID: 25843042
[TBL] [Abstract][Full Text] [Related]
36. Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma.
Aceto N; Bertino P; Barbone D; Tassi G; Manzo L; Porta C; Mutti L; Gaudino G
Eur Respir J; 2009 Dec; 34(6):1399-407. PubMed ID: 19460788
[TBL] [Abstract][Full Text] [Related]
37. Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma.
Chia PL; Russell PA; Scott AM; John T
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1235-1245. PubMed ID: 27696931
[TBL] [Abstract][Full Text] [Related]
38. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model.
Abayasiriwardana KS; Wood MK; Prêle CM; Birnie KA; Robinson BW; Laurent GJ; McAnulty RJ; Mutsaers SE
Biochem Biophys Res Commun; 2019 Mar; 510(2):198-204. PubMed ID: 30685089
[TBL] [Abstract][Full Text] [Related]
40. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
